Thursday, November 19, 2026

Healthcare Biotech Draws $77.5M as Venture Capital Creates 68 Unicorns in Q1 2026

Venture capital deployed record funding in February 2026, creating 68 new unicorns in Q1 and approaching 2025's full-year total of 187. Healthcare-focused firms led strategic biotech investments, with R1 Therapeutics securing an oversubscribed $77.5 million Series A from F-Prime, Curie.Bio, and DaVita Venture Group.

This article was written by AI. Built from the source documents listed below. How we work

Healthcare Biotech Draws $77.5M as Venture Capital Creates 68 Unicorns in Q1 2026
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Venture capital firms created 68 unicorns in Q1 2026, exceeding 2024's annual total of 117 and nearing 2025's 187. February 2026 marked record venture funding levels, with healthcare and biotechnology drawing concentrated capital deployment.

R1 Therapeutics closed an oversubscribed $77.5 million Series A round led by specialized healthcare investors F-Prime, Curie.Bio, and DaVita Venture Group. The financing will advance the company's first-in-class treatment platform, demonstrating investor appetite for clinical-stage biotech despite broader economic uncertainties.

Healthcare-focused venture firms are leading the current acceleration. F-Prime, Curie.Bio, and DaVita Venture Group represent a new class of specialized investors backing the 2026 unicorn wave. These firms concentrate capital in biotechnology companies developing novel therapeutic approaches, contrasting with generalist firms like Felicis Ventures and Amplify Partners that focus on technology exits.

The Q1 unicorn creation rate projects to 272 new unicorns annually if sustained, exceeding 2025's pace by 45%. This acceleration reflects increased capital availability and investor confidence in healthcare innovation returns. Biotechnology companies benefit from longer development timelines that insulate them from short-term market volatility while addressing structural healthcare demands.

Strategic healthcare investors bring operational expertise alongside capital. DaVita Venture Group leverages parent company DaVita's kidney care network to accelerate portfolio company commercialization. Curie.Bio focuses exclusively on life sciences, providing technical due diligence and development guidance that generalist firms cannot match.

The oversubscribed R1 Therapeutics round signals strong demand for differentiated therapeutic approaches. First-in-class treatments command premium valuations because they avoid direct competition and can establish new treatment standards. Healthcare AI applications increasingly support drug discovery and development, reducing timelines and costs for biotech startups.

February's record funding month suggests sustained capital deployment through 2026. Healthcare biotechnology attracts investors seeking recession-resistant returns, as medical needs persist regardless of economic cycles. The combination of specialized venture expertise and abundant capital creates favorable conditions for clinical-stage companies advancing novel treatments.

Source documents

Via News is a conduit. We point to the source documents behind this report: we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score5 source documents5 with a live linkVerifiability: Strong
  1. [1]News articleCrunchbase News
    5 Interesting Startup Deals You May Have Missed: Blood-Drawing Robots, Inboxes For AI Agents, Franchised Defense Manufacturing, And More
  2. [2]News articleYahoo Finance· March 17, 2026
    Gold Terra Announces Assay Results of 8.2 g/t Gold over 20.35 Metres in the Yellorex Area, Con Mine Option Property, Yellowknife, NWT
  3. [3]Press releaseGlobeNewswire· March 10, 2026
    Moxie Raises $25M Series C to Bring Clinical-Grade Operating Infrastructure to Independent Aesthetic Practices
  4. [4]Press releaseGlobeNewswire· March 17, 2026
    R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
  5. [5]News articleCrunchbase News
    The Rising Investors Behind The New Unicorn Class

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Built from 5 source documents from 3 publications, dated 10 Mar 2026 to 17 Mar 2026
  2. Published 19 Mar 2026 · Last updated 23 Mar 2026
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›
Via News Editorial Team

The Via News Editorial Team writes analysis and news from the Via News source-traceability system, under the editorial responsibility of L. Miguel Salvado, Editor. Each article is built only from source documents we hold and lists them at the end, so every claim can be checked. Articles generated with AI say so under the byline, as the EU AI Act requires.